Fenofibrate - Vectura

Drug Profile

Fenofibrate - Vectura

Alternative Names: Triglide

Latest Information Update: 14 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SkyePharma Canada; SkyePharma PLC
  • Developer Vectura
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 12 Jan 2010 Sciele Pharma is now called Shionogi Pharma
  • 09 Oct 2008 Sciele Pharma has been acquired by Shionogi
  • 16 Jun 2006 First Horizon Pharmaceutical Corporation is now called Sciele Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top